HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The cutting edge of men’s grooming

This article was originally published in The Rose Sheet

Executive Summary

Philips Norelco promotes newest iteration of its Bodygroom razor, Bodygroom+ BG2030, with "Bodygroom Manalogues" viewable at 1www.ShaveEverywhere.com. Video testimonials performed by stand-up comedian Bryan Callen chronicle "the tales of everyday men from around the globe who have overcome great grooming feats," brand says. "Despite the male tendency for being blunt, manscaping isn't exactly dinner table, or even locker room, conversation," according to Arjen Linders, VP-marketing. "The Bodygroom Manalogues infuse a little humor into the situation while still providing men with useful information they can use in their daily lives." Bodygroom+ BG2030 - with five length settings for a customized shave - is available at Target, Drugstore.com and Amazon.com for $49.99, according to Sept. 23 release. Philips Norelco's "irreverent" ShaveEverywhere.com won the firm a "Webby" Award in 2007 (2"The Rose Sheet" April 16, 2007, p. 5)

You may also be interested in...



Male Grooming Promos Capture Webby Award Nominations

Nominees for the 11 Annual Webby Awards' Best Beauty and Cosmetics Site of the Year highlight the creativity of online promotions targeting young men

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015695

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel